1. Key Insight 2. Uveitis Market Overview at a Glance 2.1. Market Share (%) Distribution of Uveitis in 2017 2.2. Market Share (%) Distribution of Uveitis in 2028 3. Disease Background and Overview: Uveitis 3.1. Introduction 3.2. Classification of Uveitis 3.3. International Uveitis Study Group (IUSG) Clinical Classification of Uveitis 3.4. The Standardization of Uveitis Nomenclature (SUN) Working Group 3.5. Symptoms of Uveitis 3.6. Pathophysiology 3.7. Etiology of Uveitis 3.8. Diagnosis of Uveitis 3.8.1. American Academy of Family Physicians 4. Epidemiology and Patient Population 4.1. Key Findings 4.2. Prevalent Population of Uveitis in the 7MM 4.3. Diagnosed Prevalent Population of Uveitis in the 7MM 4.4. Type Specific Diagnosed Prevalent Population of Uveitis in the 7MM 5. United States-Epidemiology of Uveitis 5.1. Assumptions and Rationale 5.2. Total Prevalent Population of Uveitis in the United States 5.3. Diagnosed Prevalent Population of Uveitis in the United States 5.4. Gender-Specific Diagnosed Prevalent Population of Uveitis in United States 5.5. Age-Specific Diagnosed Prevalent Population of Uveitis in United States 5.6. Type Specific Diagnosed Prevalent Population of Uveitis in United States 5.7. Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location 5.7.1. Diagnosed prevalent cases of Anterior noninfectious Uveitis (aNIU) in the United States 5.7.2. Diagnosed prevalent cases of Nonanterior NIU (Posterior Segment) or NIPU in the United States 5.8. Grade-Specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in the United States 6. EU-5 Epidemiology of Uveitis 6.1. Germany 6.1.1. Assumptions and Rationale 6.1.2. Prevalent Population of Uveitis in Germany 6.1.3. Diagnosed Prevalent Population of Uveitis in Germany 6.1.4. Gender Specific Diagnosed Prevalence of Uveitis in Germany 6.1.5. Age Group Specific Diagnosed Prevalence of Uveitis in Germany 6.1.6. Type Specific Diagnosed Prevalence of Uveitis in Germany 6.1.7. Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location 6.1.8. Grade-Specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in Germany 6.2. France 6.2.1. Assumptions and Rationale 6.2.2. Prevalent Population of Uveitis in France 6.2.3. Diagnosed Prevalent Population of Uveitis in France 6.2.4. Gender Specific Diagnosed Prevalence of Uveitis in France 6.2.5. Age Specific Diagnosed Prevalence of Uveitis in France 6.2.6. Type Specific Diagnosed Prevalence of Uveitis in France 6.2.7. Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location 6.2.8. Grade-Specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in France 6.3. Italy 6.3.1. Assumptions and Rationale 6.3.2. Prevalent Population of Uveitis in the Italy 6.3.3. Diagnosed Prevalent Population of Uveitis in Italy 6.3.4. Gender Specific Diagnosed Prevalence of Uveitis in Italy 6.3.5. Age Specific Diagnosed Prevalence of Uveitis in Italy 6.3.6. Type Specific Diagnosed Prevalence of Uveitis in Italy 6.3.7. Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location 6.3.8. Grade-Specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in Italy 6.4. Spain 6.4.1. Assumptions and Rationale 6.4.2. Prevalent Population of Uveitis in the Spain 6.4.3. Diagnosed Prevalent Population of Uveitis in Spain 6.4.4. Gender Specific Diagnosed Prevalence population of Uveitis in Spain 6.4.5. Age Specific Diagnosed Prevalence of Uveitis in Spain 6.4.6. Type Specific Diagnosed Prevalence of Uveitis in Spain 6.4.7. Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in Spain 6.4.8. Grade-Specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in Spain 6.5. United Kingdom 6.5.1. Assumptions and Rationale 6.5.2. Prevalent Population of Uveitis in the UK 6.5.3. Diagnosed Prevalent Population of Uveitis in United Kingdom 6.5.4. Gender Specific Diagnosed Prevalence of Uveitis in UK 6.5.5. Age Specific Diagnosed Prevalence of Uveitis in UK 6.5.6. Type Specific Diagnosed Prevalence of Uveitis in UK 6.5.7. Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in the UK 6.5.8. Grade-Specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in the UK 7. Japan 7.1. Assumptions and Rationale 7.2. Prevalent Population of Uveitis in the Japan 7.3. Diagnosed Prevalent Population of Uveitis in the Japan 7.4. Gender Specific Prevalence of Uveitis in Japan 7.5. Age Specific Prevalence of Uveitis in Japan 7.6. Type Specific Prevalence of Uveitis in Japan 7.7. Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in Japan 7.8. Grade-Specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in Japan 8. Treatment of Uveitis 8.1. Treatment Algorithm 8.2. First Line of Therapy: Corticosteroids 8.3. Second Line of Therapy: Immunosuppressants 8.4. Third Line of Therapy: Biologics 8.5. Guidance on Non-corticosteroid Systemic Immunomodulatory Therapy in Noninfectious Uveitis: Fundamentals of Care for Uveitis (FOCUS) Initiative 9. Unmet Needs 10. Marketed Drugs 10.1. Key Cross Competition 10.2. Durezol: Sirion Therapeutics 10.2.1. Product Description 10.2.2. Regulatory Milestones 10.2.3. Advantages & Disadvantages 10.2.4. Safety and Efficacy 10.2.5. Product Profile 10.3. Triesence: Novartis 10.3.1. Drug Description 10.3.2. Regulatory Milestones 10.3.3. Advantages & Disadvantages 10.3.4. Safety and Efficacy 10.3.5. Product Profile 10.4. Retisert: Valeant Pharmaceuticals International Inc 10.4.1. Drug Description 10.4.2. Regulatory Milestones 10.4.3. Advantages & Disadvantages 10.4.4. Safety 10.4.5. Efficacy 10.4.6. Product Profile 10.5. Ozurdex: Allergan plc 10.5.1. Drug Description 10.5.2. Regulatory Milestones 10.5.3. Advantages & Disadvantages 10.5.4. Efficacy 10.5.5. Safety 10.5.6. Product Profile 10.6. Humira: AbbVie Inc. 10.6.1. Drug Description 10.6.2. Regulatory Milestones 10.6.3. Advantages & Disadvantages 10.6.4. Safety and Efficay 10.6.5. Product Profile 10.7. Yutiq: Eyepoint Pharmaceuticals 10.7.1. Product Description 10.7.2. Clinical Development 10.7.3. Advantages & Disadvantages 10.7.4. Safety and Efficacy 10.7.5. Product Profile 10.8. Tobradex: Alcon Laboratories 10.8.1. Product Description 10.8.2. Other Developmental Activities 10.8.3. Product Profile 10.9. Acthar: Mallinckrodt 10.9.1. Product Description 10.9.2. Other Developmental Activities 10.9.3. Advantages and Disadvantages 10.9.4. Safety and Efficacy 10.9.5. Product Profile 10.10. Iluvien: Alimera Sciences 10.10.1. Product Description 10.10.2. Other Developmental Activities 10.10.3. Clinical Development 10.10.4. Clinical Trials Information 10.10.5. Safety and Efficacy 10.10.6. Product Profile 11. Emerging Drugs Analysis 11.1. Key Cross Competition 11.2. ADX-102: Aldeyra Therapeutics Inc. 11.2.1. Product Description 11.2.2. Advantages & Disadvantages 11.2.3. Clinical Development 11.2.4. Safety and Efficacy 11.2.5. Product Profile 11.3. Sirolimus: Santen 11.3.1. Product Description 11.3.2. Regulatory Milestones 11.3.3. Advantages & Disadvantages 11.3.4. Clinical Development 11.3.5. Safety and Efficacy 11.3.6. Product Profile 11.4. EGP-437: EyeGate Pharmaceuticals 11.4.1. Product Description 11.4.2. Regulatory Milestones 11.4.3. Advantages & Disadvantages 11.4.4. Clinical Development 11.4.5. Safety and Efficacy 11.4.6. Product Profile 11.5. Suprachoroidal CLS-TA: Clearside Biomedical, Inc. 11.5.1. Product Description 11.5.2. Clinical Development 11.5.3. Safety and Efficacy 11.5.4. Product Profile 11.6. Sarilumab: Sanofi Aventis 11.6.1. Product Description 11.6.2. Product Development Activities 11.6.3. Advantages and Disadvantages 11.6.4. Clinical Development 11.6.5. Safety and Efficacy 11.6.6. Product Profile 11.7. LME636 (OCS-02): Oculis Pharma 11.7.1. Product Description 11.7.2. Other development activities 11.7.3. Clinical Development 11.7.4. Safety and Efficacy 11.7.5. Product Profile 11.8. LFG316: Novartis 11.8.1. Product Description 11.8.2. Other development activities 11.8.3. Clinical Development 11.8.4. Safety and Efficacy 11.8.5. Product Profile 11.9. Abatacept (Orenica): Bristol-Myers Squibb Company 11.9.1. Product Description 11.9.2. Clinical Development 11.9.3. Safety and Efficacy 11.9.4. Product Profile 11.10. EYS606: Eyevensys 11.10.1. Product Description 11.10.2. Other development activities 11.10.3. Clinical Development 11.10.4. Safety and Efficacy 11.10.5. Product Profile 12. Uveitis: 7 Major Market Analysis 12.1. Key Findings 12.2. Market Size of Uveitis in the 7MM 12.3. Market Size of Uveitis by Therapies in the 7MM 13. United States: Market Outlook 13.1. Total Market size of Uveitis 13.2. Uveitis Market Size by Therapies 14. EU5: Market Outlook 14.1. Germany Market Size 14.1.1. Total Market size of Uveitis 14.1.2. Uveitis Market Size by Therapies 14.2. France Market Size 14.2.1. Total Market size of Uveitis 14.2.2. Uveitis Market Size by Therapies 14.3. Italy Market Size 14.3.1. Total Market size of Uveitis 14.3.2. Uveitis Market Size by Therapies 14.4. Spain Market Size 14.4.1. Total Market size of Uveitis 14.4.2. Uveitis Market Size by Therapies 14.5. United Kingdom Market Size 14.5.1. Total Market size of Uveitis 14.5.2. Uveitis Market Size by Therapies 15. Japan: Market Outlook 15.1. Japan: Market Size 15.1.1. Total Market size of Uveitis 15.1.2. Uveitis Market Size by Therapies 16. Market Drivers 17. Market Barriers 18. Appendix 19. Report Methodology 19.1. Sources Used 20. DelveInsight Capabilities 21. Disclaimer 22. About DelveInsight

Table 1 IUSG Clinical Classification of Uveitis Table 2 The SUN Working Group Anatomic Classification of Uveitis Table 3 The SUN Working Group Descriptors of Uveitis Table 4 The SUN Working Group Grading Scheme for Anterior Chamber Cells Table 5 The SUN Working Group Grading Scheme for Anterior Chamber Cells Table 6 KEY RECOMMENDATIONS FOR PRACTICE Table 7 Region-Wise Prevalent Population of Uveitis (2017–2028) Table 8 Diagnosed Prevalent Population of Uveitis (2017–2028) Table 9 Type Specific Diagnosed Prevalent Population of Uveitis in the 7MM (2017–2028) Table 10 Total Prevalent Population of Uveitis in US (2017–2028) Table 11 Total Diagnosed Prevalent Population of Uveitis in US (2017–2028) Table 12 Gender Specific Diagnosed Prevalent Population of Uveitis in the US (2017–2028) Table 13 Age-Specific Diagnosed Prevalent Population of Uveitis in the US (2017–2028) Table 14 Type-Specific Diagnosed Prevalent Population of Uveitis in US (2017–2028) Table 15 Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in the United States (2017–2028) Table 16 Grade-Specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in the United States (2017–2028) Table 17 Prevalent Population of Uveitis in Germany (2017–2028) Table 18 Diagnosed Prevalent Population of Uveitis in Germany (2017–2028) Table 19 Gender Specific Diagnosed Prevalent Population of Uveitis in Germany (2017–2028) Table 20 Age Specific Diagnosed Prevalent Population of Uveitis in Germany (2017–2028) Table 21 Type Specific Diagnosed Prevalent Population of Uveitis in Germany (2017–2028) Table 22 Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in Germany (2017–2028) Table 23 Grade-Specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in Germany (2017–2028) Table 24 Prevalent Population of Uveitis in France (2017–2028) Table 25 Diagnosed Prevalent Population of Uveitis in France (2017–2028) Table 26 Gender Specific Diagnosed Prevalent Population of Uveitis in France (2017–2028) Table 27 Age Specific Diagnosed Prevalent Population of Uveitis in France (2017–2028) Table 28 Type Specific Diagnosed Prevalent Population of Uveitis in France (2017–2028) Table 29 Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in France (2017–2028) Table 30 Grade-Specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in France (2017–2028) Table 31 Prevalent Population of Uveitis in Italy (2017–2028) Table 32 Diagnosed Prevalent Population of Uveitis in Italy (2017–2028) Table 33 Gender Specific Diagnosed Prevalent Population of Uveitis in Italy (2017–2028) Table 34 Age Specific Diagnosed Prevalent Population of Uveitis in Italy (2017–2028) Table 35 Type Specific Diagnosed Prevalent Population of Uveitis in Italy (2017–2028) Table 36 Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in Italy (2017–2028) Table 37 Grade-Specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in Italy (2017–2028) Table 38 Prevalent Population of Uveitis in Spain (2017–2028) Table 39 Diagnosed Prevalent Population of Uveitis in Spain (2017–2028) Table 40 Gender Specific Diagnosed Prevalent Population of Uveitis in Spain (2017–2028) Table 41 Age Specific Diagnosed Prevalent Population of Uveitis in Spain (2017–2028) Table 42 Type Specific Diagnosed Prevalent Population of Uveitis in Spain (2017–2028) Table 43 Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in Spain (2017–2028) Table 44 Grade-Specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in Spain (2017–2028) Table 45 Prevalent Population of Uveitis in UK (2017–2028) Table 46 Diagnosed Prevalent Population of Uveitis in UK (2017–2028) Table 47 Gender Specific Diagnosed Prevalent Population of Uveitis in UK (2017–2028) Table 48 Age Specific Prevalent Population of Uveitis in UK (2017–2028) Table 49 Type Specific Diagnosed Prevalent Population of Uveitis in UK (2017–2028) Table 50 Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in UK (2017–2028) Table 51 Grade-Specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in UK (2017–2028) Table 52 Prevalent Population of Uveitis in Japan (2017–2028) Table 53 Diagnosed Prevalent Population of Uveitis in Japan (2017–2028) Table 54 Gender Specific Prevalent Population of Uveitis in Japan (2017–2028) Table 55 Age Specific Prevalent Population of Uveitis in Japan (2017–2028) Table 56 Type Specific Prevalent Population of Uveitis in Japan (2017–2028) Table 57 Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in Japan (2017–2028) Table 58 Grade-Specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in Japan (2017–2028) Table 59 First Line of Therapy of the treatment of Uveitis, 2019 Table 60 Marketed Drugs for Uveitis Table 61 Tobradex, Clinical Trial Description, 2019 Table 62 Emerging Drugs Analysis Table 63 ADX-102, Clinical Trial Description, 2019 Table 64 Sirolimus, Clinical Trial Description, 2019 Table 65 EGP 437, Clinical Trial Description, 2019 Table 66 Suprachoroidal CLS-TA, Clinical Trial Description, 2019 Table 67 Sarilumab, Clinical Trial Description, 2019 Table 68 LME636, Clinical Trial Description, 2019 Table 69 LFG316, Clinical Trial Description, 2019 Table 70 Abatacept, Clinical Trial Description, 2019 Table 71 EYS606, Clinical Trial Description, 2019 Table 72 Market size of Uveitis by Region in USD Million (2017–2028) Table 73 Market Size of Uveitis by Therapies in the Seven Major Market (7MM),in USD Million (2017–2028) Table 74 Market Size of Uveitis in the United States, USD Million (2017–2028) Table 75 The United States Uveitis Market Size by Therapies in USD Million (2017–2028) Table 76 Market Size of Uveitis in Germany, USD Million (2017–2028) Table 77 Market Size of Uveitis by Therapies in Germany, in USD Million (2017–2028) Table 78 Market Size of Uveitis in France, USD Million (2017–2028) Table 79 Market Size of Uveitis by Therapies in France, in USD Million (2017–2028) Table 80 Market Size of Uveitis in Italy, USD Million (2017–2028) Table 81 Market Size of Uveitis by Therapies in Italy, in USD Million (2017–2028) Table 82 Market Size of Uveitis in Spain, USD Million (2017–2028) Table 83 Market Size of Uveitis by Therapies in Spain, in USD Million (2017–2028) Table 84 Market Size of Uveitis in UK, USD Million (2017–2028) Table 85 Market Size of Uveitis by Therapies in the United Kingdom, in USD Million (20172028) Table 86 Market Size of Uveitis in Japan, USD Million (2017–2028) Table 87 Market Size of Uveitis by Therapies in the Japan, in USD Million (2017–2028) Figure 1 Structure of Eye Figure 2 Types of Uveitis and Affected area Figure 3 Classification of Uveitis Figure 4 Types of Uveitis are based on the different parts of eye. Below are the four types Figure 5 Symptoms of Uveitis Figure 6 Pathogenetic mechanism of Uveitis Figure 7 Mechanism of antigen processing and presentation. Figure 8 Autoimmune conditions that cause uveitis Figure 9 Causes of Uveitis Figure 10 Diagnosis algorithm for Uveitis Figure 11 Prevalent Population of Uveitis in the 7MM (2017–2028) Figure 12 Diagnosed Prevalent Population of Uveitis in the 7MM (2017–2028) Figure 13 Type Specific Diagnosed Prevalent Population of Uveitis in the 7MM (2017–2028) Figure 14 Total Prevalent Population of Uveitis in United States (2017–2028) Figure 15 Diagnosed Prevalent Population of Uveitis in United States (2017–2028) Figure 16 Gender-Specific Diagnosed Prevalent Population of Uveitis in United States (2017–2028) Figure 17 Age-Specific Diagnosed Prevalent Population of Uveitis in the United States (2017–2028) Figure 18 Type Specific Diagnosed Prevalent Population of Uveitis in the US (2017–2028) Figure 19 Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in the United States (2017–2028) Figure 20 Grade-Specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in the United States (2017–2028) Figure 21 Prevalent Population of Uveitis in Germany (2017–2028) Figure 22 Diagnosed Prevalent Population of Uveitis in Germany (2017–2028) Figure 23 Gender Specific Diagnosed Prevalent Population of Uveitis in Germany (2017–2028) Figure 24 Age Specific Diagnosed Prevalent Population of Uveitis in Germany (2017–2028) Figure 25 Type Specific Diagnosed Prevalent Population of Uveitis in Germany (2017–2028) Figure 26 Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in Germany (2017–2028) Figure 27 Grade-Specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in Germany 2017–2028) Figure 28 Prevalent Population of Uveitis in France (2017–2028) Figure 29 Diagnosed Prevalent Population of Uveitis in France (2017–2028) Figure 30 Gender Specific Diagnosed Prevalent Population of Uveitis in France (2017–2028) Figure 31 Age Specific Diagnosed Prevalent Population of Uveitis in France (2017–2028) Figure 32 Type Specific Diagnosed Prevalent Population of Uveitis in France (2017–2028) Figure 33 Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in France (2017–2028) Figure 34 Grade-Specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in France (2017–2028) Figure 35 Prevalent Population of Uveitis in Italy (2017–2028) Figure 36 Diagnosed Prevalent Population of Uveitis in Italy (2017–2028) Figure 37 Gender Specific Diagnosed Prevalent Population of Uveitis in Italy (2017–2028) Figure 38 Age Specific Diagnosed Prevalent Population of Uveitis in Italy (2017–2028) Figure 39 Type Specific Diagnosed Prevalent Population of Uveitis in Italy (2017–2028) Figure 40 Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in Italy (2017–2028) Figure 41 Grade-Specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in Italy (2017–2028) Figure 42 Prevalent Population of Uveitis & Non-Infectious Uveitis (NIU) in Spain (2017–2028) Figure 43 Diagnosed Prevalent Population of Uveitis in Spain (2017–2028) Figure 44 Gender Specific Diagnosed Prevalent Population of Uveitis in Spain (2017–2028) Figure 45 Age Specific Diagnosed Prevalent Population of Uveitis in Spain (2017–2028) Figure 46 Type Specific Diagnosed Prevalent Population of Uveitis in Spain (2017–2028) Figure 47 Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in Spain (2017–2028) Figure 48 Grade-Specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in Spain (2017–2028) Figure 49 Prevalent Population of Uveitis in UK (2017–2028) Figure 50 Diagnosed Prevalent Population of Uveitis in UK (2017–2028) Figure 51 Gender Specific Diagnosed Prevalent Population of Uveitis in UK (2017–2028) Figure 52 Age Specific Diagnosed Prevalent Population of Uveitis in UK (2017–2028) Figure 53 Type Specific Diagnosed Prevalent Population of Uveitis in the UK (2017–2028) Figure 54 Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in the UK (2017–2028) Figure 55 Grade-Specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in the UK (2017–2028) Figure 56 Prevalent Population of Uveitis in Japan (2017–2028) Figure 57 Diagnosed Prevalent Population of Uveitis in Japan (2017–2028) Figure 58 Gender Specific Prevalent Population of Uveitis in Japan (2017–2028) Figure 59 Age Specific Prevalent Population of Uveitis in JAPAN (2017–2028) Figure 60 Type Specific Prevalent Population of Uveitis in JAPAN (2017–2028) Figure 61 Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in Japan (2017-2028) Figure 62 Grade-Specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in Japan (2017–2028) Figure 63 Treatment Regimens Figure 64 Treatment Algorithm of Uveitis Figure 65 Therapeutic algorithm in endogenous Anterior Uveitis (AU) Figure 66 Therapeutic algorithm in endogenous Intermediate Uveitis (IU) Figure 67 Therapeutic algorithm in immune-mediated posterior uveítis or panuveiti Figure 68 Management flowchart for non-infectious uveitis Figure 69 Unmet Needs Figure 70 Market size of Uveitis by Region in USD Million (2017–2028) Figure 71 Market Size of Uveitis by Therapies in the Seven Major Market (7MM), in USD Million (2017–2028) Figure 72 Market Size of Uveitis in the United States, USD Million (2017–2028) Figure 73 The United States Uveitis Market Size by Therapies in USD Million (2017–2028) Figure 74 Market Size of Uveitis in Germany, USD Million (2017–2028) Figure 75 Market Size of Uveitis by Therapies in Germany, in USD Million (2017–2028) Figure 76 Market Size of Uveitis in France, USD Million (2017–2028) Figure 77 France Uveitis Market Size by Therapies in USD Million (2017–2028) Figure 78 Market Size of Uveitis in Italy, USD Million (2017–2028) Figure 79 Italy Uveitis Market Size by Therapies in USD Million (2017–2028) Figure 80 Market Size of Uveitis in Spain, USD Million (2017–2028) Figure 81 Spain Uveitis Market Size by Therapies in USD Million (2017–2028) Figure 82 Market Size of Uveitis in United Kingdom, USD Million (2017–2028) Figure 83 United Kingdom Uveitis Market Size by Therapies in USD Million (2017–2028) Figure 84 Market Size of Uveitis in Japan, USD Million (2017–2028) Figure 85 Japan Uveitis Market Size by Therapies in USD Million (2017–2028) Figure 86 Market Drivers of Uveitis Figure 87 Market Barriers of Uveitis

Sirion Therapeutics Novartis Valeant Pharmaceuticals International Inc Allergan plc AbbVie Inc Eyepoint Pharmaceuticals Alcon Laboratories Mallinckrodt Alimera Sciences Aldeyra Therapeutics Inc Santen EyeGate Pharmaceuticals Clearside Biomedical, Inc Sanofi Aventis Oculis Pharma Bristol-Myers Squibb Company